Cargando…

Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy

Introduction. Systemic heparinisation is advocated during laparoscopic live donor nephrectomy (LDN) as a preventative measure against renal vascular thrombosis during the warm ischaemic interval. This study compares the outcome with and without the administration of systemic heparinisation. Methods....

Descripción completa

Detalles Bibliográficos
Autores principales: Crotty, Charlotte, Tabbakh, Yasmin, Hosgood, Sarah A., Nicholson, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876905/
https://www.ncbi.nlm.nih.gov/pubmed/24455192
http://dx.doi.org/10.1155/2013/138926
_version_ 1782297554772295680
author Crotty, Charlotte
Tabbakh, Yasmin
Hosgood, Sarah A.
Nicholson, Michael L.
author_facet Crotty, Charlotte
Tabbakh, Yasmin
Hosgood, Sarah A.
Nicholson, Michael L.
author_sort Crotty, Charlotte
collection PubMed
description Introduction. Systemic heparinisation is advocated during laparoscopic live donor nephrectomy (LDN) as a preventative measure against renal vascular thrombosis during the warm ischaemic interval. This study compares the outcome with and without the administration of systemic heparinisation. Methods. A retrospective analysis was performed on 186 consecutive LDN patients between April 2008 and November 2012. Systemic heparin (2000–3000 IU) was administered intravenously to donors (hep n = 109). From January 2010, heparin was not used systemically in this group of LDN (no hep n = 77). Outcome measures included donor and recipient complications, initial graft function, and 12 month graft survival. Results. The demographics of both heparinised and non-heparinised donors were similar. The warm ischaemic time (WIT) was comparable in both groups (WIT; hep 5 ± 3 versus no hep 5 ± 3 minutes; P = 1.000). There was no difference in complication rates, no episodes of graft thrombosis, and no incidences of primary nonfunction in either group. Delayed graft function occurred in 4/109 and 1/77 (3.6% versus 1.2%; P = 0.405) and there was no significant difference in graft survival (P = 0.650). Conclusion. Omitting systemic heparinisation during laparoscopic donor nephrectomy is a feasible and safe approach that does not compromise donor or recipient outcome.
format Online
Article
Text
id pubmed-3876905
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38769052014-01-16 Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy Crotty, Charlotte Tabbakh, Yasmin Hosgood, Sarah A. Nicholson, Michael L. J Transplant Clinical Study Introduction. Systemic heparinisation is advocated during laparoscopic live donor nephrectomy (LDN) as a preventative measure against renal vascular thrombosis during the warm ischaemic interval. This study compares the outcome with and without the administration of systemic heparinisation. Methods. A retrospective analysis was performed on 186 consecutive LDN patients between April 2008 and November 2012. Systemic heparin (2000–3000 IU) was administered intravenously to donors (hep n = 109). From January 2010, heparin was not used systemically in this group of LDN (no hep n = 77). Outcome measures included donor and recipient complications, initial graft function, and 12 month graft survival. Results. The demographics of both heparinised and non-heparinised donors were similar. The warm ischaemic time (WIT) was comparable in both groups (WIT; hep 5 ± 3 versus no hep 5 ± 3 minutes; P = 1.000). There was no difference in complication rates, no episodes of graft thrombosis, and no incidences of primary nonfunction in either group. Delayed graft function occurred in 4/109 and 1/77 (3.6% versus 1.2%; P = 0.405) and there was no significant difference in graft survival (P = 0.650). Conclusion. Omitting systemic heparinisation during laparoscopic donor nephrectomy is a feasible and safe approach that does not compromise donor or recipient outcome. Hindawi Publishing Corporation 2013 2013-12-16 /pmc/articles/PMC3876905/ /pubmed/24455192 http://dx.doi.org/10.1155/2013/138926 Text en Copyright © 2013 Charlotte Crotty et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Crotty, Charlotte
Tabbakh, Yasmin
Hosgood, Sarah A.
Nicholson, Michael L.
Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy
title Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy
title_full Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy
title_fullStr Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy
title_full_unstemmed Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy
title_short Systemic Heparinisation in Laparoscopic Live Donor Nephrectomy
title_sort systemic heparinisation in laparoscopic live donor nephrectomy
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876905/
https://www.ncbi.nlm.nih.gov/pubmed/24455192
http://dx.doi.org/10.1155/2013/138926
work_keys_str_mv AT crottycharlotte systemicheparinisationinlaparoscopiclivedonornephrectomy
AT tabbakhyasmin systemicheparinisationinlaparoscopiclivedonornephrectomy
AT hosgoodsaraha systemicheparinisationinlaparoscopiclivedonornephrectomy
AT nicholsonmichaell systemicheparinisationinlaparoscopiclivedonornephrectomy